Dias Alexander, Brook Mark N, Bancroft Elizabeth K, Page Elizabeth C, Chamberlain Anthony, Saya Sibel, Amin Jan, Mikropoulos Christos, Taylor Natalie, Myhill Kathryn, Thomas Sarah, Saunders Edward, Dadaev Tokhir, Leongamornlert Daniel, Dyrsø Jensen Thomas, Evans D Gareth, Cybulski Cezary, Liljegren Annelie, Teo Soo H, Side Lucy, Kote-Jarai Zsofia, Eeles Rosalind A
Oncogenetics Team The Institute of Cancer Research London UK.
Instituto Nacional de Cancer Jose de Alencar Gomes da Silva INCA Rio de Janeiro Brazil.
BJUI Compass. 2023 Jan 9;4(3):361-373. doi: 10.1002/bco2.156. eCollection 2023 May.
The relation of serum androgens and the development of prostate cancer (PCa) is subject of debate. Lower total testosterone (TT) levels have been associated with increased PCa detection and worse pathological features after treatment. However, data from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) and Prostate Cancer Prevention (PCPT) trial groups indicate no association. The aim of this study is to investigate the association of serum androgen levels and PCa detection in a prospective screening study of men at higher genetic risk of aggressive PCa due to pathogenic variants (PVs), the IMPACT study.
Men enrolled in the IMPACT study provided serum samples during regular visits. Hormonal levels were calculated using immunoassays. Free testosterone (FT) was calculated from TT and sex hormone binding globulin (SHBG) using the Sodergard mass equation. Age, body mass index (BMI), prostate-specific antigen (PSA) and hormonal concentrations were compared between genetic cohorts. We also explored associations between age and TT, SHBG, FT and PCa, in the whole subset and stratified by PVs status.
A total of 777 participants in the IMPACT study had TT and SHBG measurements in serum samples at annual visits, giving 3940 prospective androgen levels, from 266 PVs carriers, 313 PVs carriers and 198 non-carriers. The median number of visits per patient was 5. There was no difference in TT, SHBG and FT between carriers and non-carriers. In a univariate analysis, androgen levels were not associated with PCa. In the analysis stratified by carrier status, no significant association was found between hormonal levels and PCa in non-carriers, or PVs carriers.
Male 1/2 PVs carriers have a similar androgen profile to non-carriers. Hormonal levels were not associated with PCa in men with and without PVs. Mechanisms related to the particularly aggressive phenotype of PCa in PVs carriers may therefore not be linked with circulating hormonal levels.
血清雄激素与前列腺癌(PCa)发生发展之间的关系存在争议。总睾酮(TT)水平较低与PCa检出率增加以及治疗后更差的病理特征相关。然而,度他雄胺降低前列腺癌事件(REDUCE)和前列腺癌预防(PCPT)试验组的数据表明二者并无关联。本研究的目的是在一项针对因致病变异(PVs)而具有较高侵袭性PCa遗传风险男性的前瞻性筛查研究(IMPACT研究)中,调查血清雄激素水平与PCa检出之间的关联。
参与IMPACT研究的男性在定期就诊时提供血清样本。使用免疫测定法计算激素水平。游离睾酮(FT)通过Sodergard质量方程由TT和性激素结合球蛋白(SHBG)计算得出。比较不同遗传队列之间的年龄、体重指数(BMI)、前列腺特异性抗原(PSA)和激素浓度。我们还在整个亚组以及按PVs状态分层的情况下,探讨了年龄与TT、SHBG、FT和PCa之间的关联。
IMPACT研究中共有777名参与者在年度就诊时对血清样本进行了TT和SHBG测量,共得到3940个前瞻性雄激素水平数据,来自266名PVs携带者、313名PVs携带者和198名非携带者。每位患者的就诊中位数为5次。携带者与非携带者之间的TT、SHBG和FT并无差异。在单因素分析中,雄激素水平与PCa无关。在按携带者状态分层的分析中,非携带者或PVs携带者的激素水平与PCa之间均未发现显著关联。
男性1/2 PVs携带者的雄激素谱与非携带者相似。无论有无PVs男性,激素水平均与PCa无关。因此,与PVs携带者中PCa特别侵袭性表型相关的机制可能与循环激素水平无关。